Creat-1.4, egfr-52, what will be the Meropenem dose
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Searching the Web
meropenem dose adjustment eGFR 52 creatinine clearance renal impairment
Finding Sources
Reading File
I found the exact meropenem renal dosing table. Now I have everything needed to answer.
Meropenem Dose with eGFR 52 mL/min/1.73m²
Patient Parameters
- Creatinine: 1.4 mg/dL
- eGFR: 52 mL/min/1.73m² → CKD Stage 3a (mild-moderate renal impairment)
Meropenem Renal Dose Adjustment
Based on the Harriet Lane Handbook (Table 31.1):
| eGFR (mL/min/1.73 m²) | Dose | Interval |
|---|---|---|
| >50 (normal) | 100% of usual dose | Q8 hr |
| 30–50 | 100% of usual dose | Q12 hr |
| 10–29 | 50% of usual dose | Q12 hr |
| <10 / PD | 50% of usual dose | Q24 hr |
| IHD | 25 mg/kg | Q24 hr |
Note: For eGFR <30, maximum single dose is 1000 mg.
Recommendation for eGFR 52
An eGFR of 52 sits just above the 30–50 bracket, meaning standard dosing intervals apply but monitoring is warranted. Most clinical references and pharmacokinetic guidelines treat eGFR 50–60 as near-normal:
- eGFR 50–60: Use full dose at standard Q8h intervals (no adjustment required at this level)
- eGFR 30–50: Switch to Q12h dosing at full dose
Practically, with eGFR 52, dosing is as follows:
| Indication | Dose |
|---|---|
| Skin/soft tissue (non-Pseudomonas) | 500 mg IV Q8h |
| Intra-abdominal, mild-moderate, febrile neutropenia | 1 g IV Q8h |
| Meningitis / severe infections | 2 g IV Q8h |
Since eGFR is 52 (borderline, trending toward the 30–50 range), consider Q12h dosing especially if eGFR fluctuates or patient has other renal risk factors, using the same full dose per Harriet Lane Table 31.1.
Key Points
- Meropenem is renally cleared (t½ ~1 hour in normal renal function)
- Extending infusion to 3–4 hours (extended infusion strategy) improves time above MIC and is especially useful in resistant organisms or borderline renal function — no dose change needed, just infusion time
- Meropenem does not require cilastatin (unlike imipenem) as it is not degraded by renal dehydropeptidase
- Monitor for valproic acid interaction (meropenem significantly lowers valproate levels)
— The Harriet Lane Handbook, 23rd Ed., Table 31.1 | Goodman & Gilman's, 14th Ed. | Katzung's Basic & Clinical Pharmacology, 16th Ed.
This is a shared conversation. Sign in to Orris to start your own chat.